New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects (Q38199573)

30 August 2017

title

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects (English)

1 reference

30 August 2017

1

1 reference

30 August 2017

6

1 reference

30 August 2017

Timothy D McHugh

7

0 references

Stephen H Gillespie

object named as

Stephen H Gillespie

2

0 references

Markus Maeurer

object named as

Markus Maeurer

9

0 references

Michael Hoelscher

3

object named as

Michael Hoelscher

1 reference

30 August 2017

5

Stewart T Cole

1 reference

30 August 2017

Patrick P J Philips

4

1 reference

30 August 2017

Marco Schito

8

1 reference

30 August 2017

Andrew J Nunn

10

1 reference

30 August 2017

publication date

1 April 2014

1 reference

Lancet Infectious Diseases

30 August 2017

published in

1 reference

30 August 2017

volume

14

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

327-340

1 reference

Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Streptomycin, a Substance Exhibiting Antibiotic Activity Against Gram-Positive and Gram-Negative Bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

STREPTOMYCIN treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The Influence of Adverse Conditions upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Targeting persisters for tuberculosis control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Drug-resistant tuberculosis: time for visionary political leadership

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

1 reference

7 January 2021

Advances in the development of new tuberculosis drugs and treatment regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Tuberculosis drug discovery in the post-post-genomic era

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The added effect of thioridazine in the treatment of drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Linezolid for the treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The challenge of new drug discovery for tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Delamanid for multidrug-resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Targeting dormant bacilli to fight tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Lipoamide Channel-Binding Sulfonamides Selectively Inhibit Mycobacterial Lipoamide Dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 Years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Dangers of non-specific composite outcome measures in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Design issues in pivotal drug trials for drug sensitive tuberculosis (TB).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Comparison of time to positive and colony counting in an early bactericidal activity study of anti-tuberculosis treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Tuberculosis biomarkers discovery: developments, needs, and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Quantitative analysis of mRNA as a marker for viability of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

High rates of recurrence in HIV-infected and HIV-uninfected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Timing of initiation of antiretroviral drugs during tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Tuberculosis vaccine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Biologics and infections: lessons from tumor necrosis factor blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Understanding latent tuberculosis: a moving target

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Systems level immune response analysis and personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Microevolution of extensively drug-resistant tuberculosis in Russia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Sustainable tuberculosis drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970328-1

7 January 2021

10.1016/S1473-3099(13)70328-1

Identifiers

DOI

1 reference

30 August 2017

1 reference